Amgen Reports Third Quarter 2021 Financial Results
Amgen today announced financial results for the third quarter of 2021. Key results include: Total revenues increased 4% to $6.7 billion in comparison to the third quarter of 2020, driven by higher unit demand, partially offset by lower net selling prices. Product sales increased 4% globally, driven by double-digit volume growth across a number of our products, including Prolia ® EVENITY ® Repatha ® and MVASI ® . ...